Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Merck Sharp & Dohme LLC
Nurix Therapeutics, Inc.
AbbVie
Rigshospitalet, Denmark
Beth Israel Deaconess Medical Center
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
University of Chicago
Gilead Sciences
University of Washington
Mayo Clinic
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Dana-Farber Cancer Institute
Ascentage Pharma Group Inc.
Mayo Clinic
Newave Pharmaceutical Inc
Schrödinger, Inc.
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
BeOne Medicines
Eli Lilly and Company
AbbVie
BeOne Medicines
BeOne Medicines
Acerta Pharma BV
Carna Biosciences, Inc.
University of Ulm
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University Hospital, Lille
University of Ulm
Acerta Pharma BV
French Innovative Leukemia Organisation
Massachusetts General Hospital
BeOne Medicines
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Mayo Clinic
City of Hope Medical Center
Accutar Biotechnology Inc
Ohio State University Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Northwell Health